Trump Nominates Dr. Nicole Saphier as Next Surgeon General

Donald Trump turned to Dr. Nicole Saphier for his next surgeon general pick after his earlier nominee, Casey Means, stalled in the Senate over questions about her experience and her views on vaccines. The move puts a breast-imaging specialist and Fox News medical contributor into the center of a job that has long been one of Washington’s most visible public-health megaphones.

The surgeon general is nominated by the president, confirmed by the Senate and serves a four-year term. The office, housed within the U.S. Department of Health and Human Services, is described by the federal government as the Nation’s Doctor and oversees the U.S. Public Health Service Commissioned Corps, a uniformed force of more than 6,000 public-health professionals. Since 1871, the post has been the federal government’s leading public-health spokesperson, with the power to issue advisories, calls to action and reports on major health threats.

Trump’s selection of Saphier also signals what kind of messenger he wants after withdrawing Means. Reuters reported that Saphier is Trump’s third nominee for the post, underscoring how unsettled the search has been. Means’ nomination lost momentum in the Senate amid scrutiny of her background and vaccine views, making the surgeon general fight less about a single public-health résumé than about who can survive political and ideological vetting on Capitol Hill.

Saphier brings a different profile. She is the director of breast imaging at Memorial Sloan Kettering Monmouth and also sees patients at Memorial Sloan Kettering Cancer Center’s Manhattan location. Her clinical and research focus is breast cancer screening, diagnosis and intervention. She is also an associate professor at Weill Cornell Medical College and a medical contributor at Fox News, a combination that gives her both specialist credentials and a national media platform.

Trump praised Saphier on social media as a "STAR physician" who has spent her career guiding women facing breast cancer through diagnosis and treatment while advocating for early cancer detection and prevention. That framing suggests a nomination built on more than pure policy alignment. It points to a surgeon general who can speak with the authority of a doctor, but also with the reach of a television regular.

The contrast with recent surgeon general politics is sharp. The job has often been pulled into broad national debates over opioids, e-cigarettes, COVID-19 and mental health, and the next nominee will inherit that public-facing burden. Whether Saphier becomes a credentials-first choice, a loyalty-first choice, or both will now be tested in the Senate.